The use of natural remedies to treat osteoarthritis

Boon Hooi Tan1,2, Chin Eng Ong2

1Division of Human Biology, School of Medicine, International Medical University, Jalan Jelutong Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia. 2School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150 Bandar Sunway, Selangor, Malaysia

ABSTRACT

Osteoarthritis (OA) is the leading medical condition for which patients use alternative treatments including the natural remedies. The aim of this review is to describe the dietary supplements and herbal remedies most commonly used in patients with osteoarthritis with an emphasis on the efficacy and safety of these natural remedies. Glucosamine and chondroitin sulfate, two of the molecular building blocks found in articular cartilage, are the most commonly used remedies in OA treatment. Most clinical researches suggest that glucosamine and chondroitin show efficacy in reducing or improving symptoms and their ability to arrest progression of the disease or regenerate damaged cartilage. Patented formulations of both remedies are recommended by several therapeutic guidelines for use as first line background OA treatment. Reliable evidence that the combination is more effective than either agent alone is however still lacking. Several other herbs or remedies are promoted for treating osteoarthritis such as S-adenosylmethionine, methylsulfonylmethane, Harpagophytum procumbens (devil’s claw), Curcuma longa (turmeric), Zingiber officinale (ginger), and capsaicin but there is no reliable evidence on long-term efficacy or safety. The clinical usefulness of these remedies is therefore rather limited currently.

Keywords osteoarthritis, natural remedies, glucosamine, chondroitin, herbs

INTRODUCTION

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by damage of articular cartilage and concomitant changes to other articular structures, such as bones, synovium, ligaments, menisci, joint capsules, bursae, and peri-articular muscles (Altman, 2009). It is the most prevalent chronic rheumatic disease that affects women more frequently than men in the aging group and also a major cause of pain and disability in most countries around the globe (Fransen et al., 2011). Most of this disability is attributable to the hips and knees that impairs quality of life, giving significant impact on healthcare costs, employer costs and job performance, and eventually causes enormous economic burden.

The current medical treatments for osteoarthritis using analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are focused on relieving pain and symptoms but none are proven to potentially delay the disease progression (Rainsford, 1999). Moreover, NSAIDs are often associated with serious adverse effects in long-term use, such as gastric ulceration, hepatic toxicity, and haemorrhage (Rainsford, 1999; Wolfe et al., 1999). Furthermore, the role of NSAIDs on OA progression remains controversial. Some NSAIDs such as indomethacin are associated with negative effects on chondrocytes and cartilage matrix formation (Owens et al., 2004) while others (such as nimesulide and naproxen) have chondroprotective effects via increase synthesis of the matrix component (Cheleschi et al., 2015; Notomi et al., 2000). Due to the concern for side effects of NSAIDs and its uncertainty on the cartilage function, patients have opted for safer alternatives that are symptom-modifying and structure-modifying, including herbs, dietary supplements, and non-pharmacological modalities such as physical therapy, acupuncture, exercise and electromagnets (Morelli et al., 2003). Numerous dietary/herbal supplements or formulations targeting patients with OA have been introduced into the market, such as glucosamine, chondroitin, S-adenosylmethionine, methylsulfonylmethane, devil’s claw, turmeric, ginger and capsacin, but not all of them are proven for long-term safety and effectiveness (Gregory et al., 2008).

This review summarizes the efficacy and safety of these remedies which will be discussed in two broad categories: dietary supplements and herbal medicines. Table 1 enlists these natural remedies for OA which will be discussed in the following sections of this review.

DIETARY SUPPLEMENTS FOR OSTEOARTHRITIS

Glucosamine

Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar biosynthesized endogenously in animals and human, with a molecular mass of 179.17 Da. It is water-soluble, with pKa of 7.52 at 20°C and 6.91 at 37°C (Semikar and Rovati, 2001). It is necessary for the generation of glycoprotein and glycosaminoglycans, notably found in synovial fluid, ligaments, and other joint structures. These glycosaminoglycans are repeating disaccharide units which are linked together in long chains to a core protein to form the proteoglycan molecule. These proteoglycan molecules are further linked together on one hyaluronic acid filament forming large aggregate
Table 1. Natural remedies for osteoarthritis

<table>
<thead>
<tr>
<th>Remedy</th>
<th>Typical dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucosamine</td>
<td>1,500 mg once daily or 500 mg three times daily</td>
<td>A SYSADOA recommended for use as part of the background treatment for OA; evidence is generally positive with some inconsistencies; glucosamine sulfate preferred over glucosamine hydrochloride</td>
</tr>
<tr>
<td>Chondroitin</td>
<td>200–400 mg two or three times daily</td>
<td>A SYSADOA recommended for use as part of the background treatment for OA; inconsistent evidence with mixed positive and negative results; combination chondroitin glucosamine better than glucosamine sulfate or chondroitin alone in some studies</td>
</tr>
<tr>
<td>S-aloeosrinicifolium</td>
<td>600 – 1,000 mg daily in 2 to 3 divided doses</td>
<td>Inconsistently evidence; intramolecular salt forms preferred for both stability and bioavailability</td>
</tr>
<tr>
<td>Methylsulfonylmethane</td>
<td>2 to 6 g daily in 2 to 3 divided doses</td>
<td>Not recommended because of insufficient evidence</td>
</tr>
</tbody>
</table>

**Herbal medicines**

<table>
<thead>
<tr>
<th>Herbal medicine</th>
<th>Typical dosage</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helix pomatia procumbens      (devil’s claw)</td>
<td>2.4 to 2.6 g daily standardized extract</td>
<td>Chronic administration is not recommended because of insufficient long-term safety data</td>
</tr>
<tr>
<td>Curcuma longa (tumeric)</td>
<td>No typical dosage for osteoarthritis</td>
<td>Not recommended because of insufficient evidence</td>
</tr>
<tr>
<td>Zingiber officinale (ginger)</td>
<td>510 mg daily standardized extract</td>
<td>Not recommended because of insufficient evidence</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>Daily topical application in concentrations of 0.025 to 0.075%</td>
<td>Inconsistent evidence with mixed positive and negative results; insufficient long-term safety data</td>
</tr>
</tbody>
</table>

proteoglycan macromolecule, of which its moiety gives hyaline cartilage a viscous, elastic resiliency and allows it to act as a cushion. Hyaline cartilage is highly specialized connective tissue comprising chondrocytes and matrix made of collagen and proteoglycan molecules. Therefore the maintenance of articular cartilage and joint architecture depends on the balance between degradation and synthesis of these matrix components. The use of glucosamine in treating arthritis pain can be dated as far back as 1960s (Vetter, 1969) and now it is the most commonly used remedy among osteoarthritis patients. In fact, the current clinical guidelines on OA treatment have recommended the use of glucosamine, and/or chondroitin, as the first line background treatment in conjunction with parallel non-pharmacological therapies (such as weight loss, exercise program, joint braces, assist, walking aids and acupuncture) in OA patients (Brouwer et al., 2014). Both supplements are currently classified as Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOAs) in the therapeutic guidelines and are used together with an added paracetamol for symptomatic relief in patients. Glucosamine is available in multiple forms as over-the-counter supplement, normally in stabilized salt form due to the presence of positively charged amino group of glucosamine at physiological pH that are able to form different conjugates or salts. The widely used forms are glucosamine hydrochloride and glucosamine sulfate (Fig. 1). Exogenous glucosamine is derived from chitin, a polymer present in marine exoskeletons, such as shell fish, or produced synthetically. These exogenous glucosamine may exhibit anti-inflammatory effects and offer a delayed but progressive and longer lasting effect compared to NSAIDs (Brouwer, 2004; Rovati et al., 1999). Moreover, exogenous glucosamine serves mainly as substrate for synthesis of polymers and glycosaminoglycans of joint and bones (Semark and Rovati, 2001) and thus, contributes to restoration of damaged cartilage (Brouwer, 2004). Recent in vitro studies have demonstrated that glucosamine acted as a scavenger of free oxygen radicals and was able to control the expression of inflammatory genes and proteins in human chondrocytes (Culham et al., 2010; Lange et al., 2003). Many pro-inflammatory factors were found to be reduced by glucosamine including interleukin-1β (IL-1β), tumour necrosis factor (TNF-α), metalloproteases, prostaglandin (PG) E₂, as well as superoxide dismutase 2 (Culham et al., 2010; Lange et al., 2003). A recent Cochrane Review (by the Cochrane Collaboration) has highlighted high-quality trials of the presented glucosamine formulation (crystalline glucosamine sulphate) which showed the superiority of the formulation to placebo in the treatment of pain and functional impairment (Towheed et al., 2009). These trials were long-term studies of 3 months to 5 years duration in OA patients of mild to moderate severity and the results have demonstrated improved in disease symptoms, joint function and structural changes in patients (Herrero-Boumsell et al., 2007; Pavelka et al., 2002; Regimin et al., 2001). Glucosamine is usually taken orally at 1,500 mg once daily or 500 mg three times daily, in sulfate or the hydrochloride salt form, or in combination with chondroitin sulfate and methylsulfonylmethane. In terms of pharmacokinetics, the salts of glucosamine are tolerated in the stomach, making it available for absorption in the small intestine (Houpt et al., 1999). In humans, 90% of orally administered glucosamine is absorbed from the small intestine. After metabolism in liver, the metabolites of glucosamine are excreted mainly in urine along with the unchanged glucosamine, with a small amount eliminated in the feces (Semark and Rovati, 2001). Due to the first pass metabolism, the bioavailability of orally administered glucosamine is only 25% compared with intravenous administration, which achieves bioactivity of 98% (Benchle et al., 1998). The entry of glucosamine into cells is dependent on stimulation by union with the aid of the glucose transporter system (Pouwels et al., 2001). Healthy humans produce serum glucosamine concentration of around 0.04 mM and would achieve serum level of approximately 0.05 mM after oral intake of glucosamine (Anderson et al., 2005; Pouwels et al., 2001). Acute toxicity studies in animals indicated that very high doses (5,000 – 15,000 mg/kg) of orally administered glucosamine were well tolerated without reports of toxicity, showing a median LD50 value at 8,000 mg/kg (Anderson et al., 2005). Besides, glucosamine is unlikely to cause mutagenicity.
Chondroitin

Chondroitin is a negatively charged high molecular weight (10 - 50 kDa) glycosaminoglycan available abundantly in connective tissue and cartilage. It is a natural polymer of a disaccharide comprising repeating sequence of N-acetylgalactosamine and sulfated N-acetylgalactosamine residues that are connected by β-1,4-galactosamine and β-1,3 heparosamine bonds (Huskisson, 2008). As the major constituent of articular cartilage, chondroitin is essential for the structural and functional integrity of the joints (Lippiello et al., 2000).

Chondroitin is hydrophilic and tends to produce viscous solution when mixed with water (similar to sodium hyaluronate), and thus it initiatively helps to stimulate cartilage repair, maintains the viscosity in joints, and inhibits enzymes that degrade cartilage (Deal and Moskowitz, 1999). These properties could result clinically in pain relief and improved joint function in patients with OA as well as in decelerated joint destruction.

Chondroitin as a supplement is produced from animal sources, including shark cartilage and bovine trachea. This supplement, normally in the form of chondroitin sulfate, is orally administered in two or three daily doses of 400 mg (Jackson et al., 2010). The commercially available chondroitin sulfate is normally marketed as co-ingredient with glucosamine. Chondroitin is larger in molecular size and not as well absorbed as glucosamine (Deal and Moskowitz, 1999). It goes through partial digestion in the gastrointestinal tract and an extensive first pass effect, as occurs with other glycosaminoglycans, producing high molecular weight forms or oligosaccharides (Romac and Conte, 1993). Further breakdown of these products produces mainly the unsaturated disaccharides derived from the chondroitin sulfate molecule itself, including 2-acetamido-2-deoxy-3-O-β-D-glucuronic acid-4-sulfate [Adi-0S], 2-acetamido-2-deoxy-3-O-β-D-glucuronic acid-4-sulfate [Adi-UA2S], 2-acetamido-2-deoxy-3-O-β-D-glucuronic acid-4-sulfate [Adi-UA5S] and 2-acetamido-2-deoxy-3-O-β-D-glucuronic acid-6-O-sulfate [Adi-6S]. The chemical structures of these derivatives stabilized in the form of sodium salt are depicted in Fig. 2.

These disaccharides are typically detectable in human blood circulation following administration, with high concentration of both Adi-0S and Adi-6S and only trace amounts of Adi-0S and Adi-UA-2S (Jackson et al., 2010; Okazaki et al., 1995).

Chondroitin sulfate is absorbed to small extent in the small intestine (< 10%), while in the distal gastrointestinal tract, it serves as a probiotic and is digested further by the enzymes in the intestinal flora to smaller molecules (Härte et al., 2004). Bioavailability of chondroitin has been estimated at 12 - 13% (Lamari et al., 2006). The elimination half-lives of oral administered chondroitin sulfate in humans was found to be approximately 5 to 6 hours. About 37 to 50% of the administered chondroitin sulfate is excreted in the urine during the first 24 hours in the form of high and low molecular weight derivatives (Romac and Conte, 1993).

As with the case of glucosamine, chondroitin is a NO-SADOA recommended for use as part of the background treatment for OA (Brüere et al., 2014). Many clinical studies have confirmed the effectiveness of chondroitin in reducing pain and improving joint mobility in the knee of OA patients (Bques and Poor, 1998; Kahal et al., 2000; Mazieres et al., 2007; Uebelhart et al., 2004) as well as lowering the number of joints involved in osteoarthritis erosions (Rovetto et al., 2002).

These studies were medium - to long-term studies of 6 months to 2 years treatment in OA patients and the results have demonstrated improvement in pain control, joint function and significant reduction in the rate of joint space narrowing. Data from these studies hence have provided evidence for the long-term combined structure-modifying and symptom-modifying effects of chondroitin. The therapeutic effects of chondroitin above have been demonstrated to be related to its in vivo

Fig. 1 Chemical structures of glucosamine hydrochloride and the common forms of sulfated-glucosamine.

Fig. 2 Chemical structures of the common disaccharide salt forms of chondroitin sulfate.
activities. In human articular chondrocyte or cartilage cultures, chondroitin was able to increase the growth of proteoglycans by inhibition of leukocyte elastase, a serine protease which degrades proteoglycans and matrix components (Bassleer et al., 1998). Chondroitin also counteracted IL-1β-induced cartilage damage, including inhibition of activity of chondrocytic metalloproteinases and PGE2 release, as well as nitric oxide (NO)-induced apoptosis (Bassleer et al., 1998; Montfort et al., 2003).

The use of glucosamine and chondroitin is believed to bridge symptomatic and preventive approach since these compounds may have the ability to maintain and rebuild cartilage, with beneficial consequences on both chronic joint pain and progression of joint degeneration. In vivo study and clinical data further indicate that combined use of glucosamine and chondroitin sulfate may have synergistic effect (Fransen et al., 2015; Lippiello et al., 2010), but this effect is somehow inconclusive (Jackson et al., 2010).

Other dietary supplements
S-adenosylhomocysteine (SAM) is a supplement to treat OA, and also other conditions such as liver disease and depression. It appears to improve chondrocytes and cartilage thickness and may also reduce cytokine-mediated cartilage destruction (Barcelo et al., 1987). Research on the use of SAM for OA however has not been consistent. While some studies have shown its effectiveness in reducing osteoarthritic pain (Maccagno et al., 1987; Nguyen et al., 2004), SAM can take several weeks of treatment before symptoms improve. Furthermore, as a supplement that requires daily intake, SAM can be expensive (a monthly supply normally costs USD 60-120). Product quality is another concern as SAM is inherently an unstable compound which tends to lose its activity upon storage on the shelves. Hence, SAM may not be a reliable treatment option.

Methylsulfonylmethane (MSM) is typically formulated in combination with glucosamine and/or chondroitin in commercially available supplements. It is promoted as possessing analgesic and anti-inflammatory effects. Preliminary studies in animal models suggest that it may decrease degenerative processes in joints (Ezoko et al., 2013). Clinical trials however yield inconsistent results with modest degree of pain reduction but no effect on joint stiffness (Kim et al., 2006; Utsa and Naidu, 2004). In addition, most clinical trials conducted on MSM have been short term and convincing evidence of its long-term efficacy and safety is rather limited, MSM should therefore not be recommended for OA.

HARPAGOPHYTUM PROCNOMBS (Devil’s claw)
Harpagophytum procumbens (Pedalaceae) is an important herbal plant naturally found in the Kalahari region of southern Africa (Van Wyk et al., 2008). The indigenous San and Khoi people in this region have had a long history of use of H. procumbens, its use was later adopted by immigrating Bantu-speakers (Stewart and Cole, 2005). Established ethnobotanical uses of H. procumbens include fever, blood diseases, gastrointestinal problems, postpartum pain, diabetes, hypertension, urinary tract infections, sores, ulcers and birth (Stewart and Cole, 2005). Recent scientific studies show that the herb is effectively used for treatment of inflammatory diseases including degenerative rheumatoid arthritis, osteoarthritis, and tendinitis (Brian et al., 2006; Conrowzer et al., 2014; Gagnier et al., 2007). H. procumbens is currently listed in the European Pharmacopoeia as a remedy to treat rheumatism and arthritic ailments (Macwangu et al., 2012; Stewart and Cole, 2005) Amongst the main constituents of the herb include a number of iridoid glycosides such as harpagoside, harpagide, procumbide and 8-coumaroylharpagide (Brian et al., 2006). The iridoids, a large group of cyclopentanepyrane monoterpenoids, are considered as key bioactive constituents. The chemical structures of these iridoids are depicted in Fig. 3. The content of harpagoside, the major iridoid (at 1.2% according to the European Pharmacopoeia), is in fact used to standardize commercial H. procumbens products. Other constituents include phenylethanol derivatives such as verbacoside and isoacetoside, as well as oligosaccharides (Clarkson et al., 2006).

A number of studies have been carried out to prove in vitro and in vivo anti-inflammatory activity for H. procumbens extracts and isolated compounds. In vitro activities include the inhibition of lipoxygenase(LPS)–induced release of cytokines (IL-6, IL-1β, TNF-α) and PGE2 from human monocytes (Elibisch et al., 2004); reduction of IL-induced synthesis of metalloproteinases in human chondrocytes (Schulze-Tanzil et al., 2004); the inhibition 12-O-tetradecanoylphorbol-13-acetate (TPA)–induced COX (cyclooxygenase)-2 expression in human breast epithelial cells (Na et al., 2004), and the suppression of PGE2 and NO biosynthesis by inhibiting LPS-induced activation of the COX-2 and iNOS (inducible nitric oxide synthase 2) mRNA expressions in L929 cells (Jeng et al., 2005). A number of in vivo studies have also been performed for its anti-inflammatory activity. Methanolic extract of H. procumbens was shown to inhibit COX-2 expression induced by tumour promoter in mouse skin and to inhibit TPA mediated DNA-binding of nuclear factor kappa B cells (NF-kB) (Kundu et al., 2005; Na et al., 2004). H. procumbens administration caused significantly lower paw thickness in Freund’s adjuvant-induced arthritis rat models, showing similar effect to the positive control indomethacin (Ahn et al., 2005). In addition, the herb was found to decrease the number of circulating leukocytes in normal rats (Catelon et al., 2006).

The effectiveness of H. procumbens as anti-inflammatory, analgesic and antiarthritic agents have been examined in some clinical studies. Brian et al. (2010) reviewed the clinical trial literature from 1966 to 2006 on the efficacy of H. procumbens in the treatment of OA and found that many trials did not conform to important methodological quality criteria, the data from the higher quality studies however indicated that H. procumbens appeared effective in improving the main clinical symptom of pain. A Cochrane Review of herbal medicine used to treat lower back pain found two good quality
Natural remedies for osteoarthritis

trials utilising Zingiber officinale. One trial has provided strong evidence for short-term improvements in pain for daily doses of Zingiber officinale standardised to 50 mg or 100 mg harpagoside. Another one demonstrated that Zingiber officinale product was equivalent to 12.5 mg per day of the anti-inflammatory drug rofecoxib in symptomatic control (Gagnier et al., 2007). However, before the full potential of Zingiber officinale extracts and harpagoside as a new anti-inflammatory drug can be realised more work is required: effects of its long-term administration in chronic models of joint inflammation should be examined, and its efficacy must be elucidated in more rigorously controlled long-term clinical trials. In addition, more detailed studies of the mechanism of action, safe and optimal administration methods and the zimarin effective doses should be investigated. These further studies are required to enable the acceptance of the herb and/or its constituents as a therapeutic agent for OA.

Curcuma longa (Turmeric)

Curcuma longa (turmeric) is a spice used frequently in curry powders, and has been used for medical purposes for years, mostly in Asian countries (Kumar et al., 2015). The bioactive constituent is curcumin, a curcuminoid pigment extracted from the rhizomes of C. longa that gives the yellow colour to some foods. Anti-inflammatory action of curcumin has been ascribed to inhibition of COX-2, prostaglandin, and leukotrienes (Park et al., 2012). It has also been shown to ameliorate inflammatory responses by down-regulating the expression of inflammatory cytokines and acute phase proteins (Cho et al., 2007; Jin et al., 2007). Moreover, curcumin possesses antiarthritic property by modulating the growth of collagen and synovial fibroblasts (Huang et al., 2015; Park et al., 2007), as well as by regulating bone turnover (Kim et al., 2012). Clinical trials have not examined the use of turmeric for OA treatment; however, some preliminary clinical studies indicate that it may provide symptomatic relief of rheumatoid arthritis (Doodhar et al., 1990). As a spice in foods, turmeric is generally safe to consume, and it also appears to be well tolerated when used in short term for medical purposes. However, from the formulation and pharmacokinetic perspective, the therapeutic value of curcumin and other related curcuminoinds is currently rather limited due to problems associated with low sensitivity, low water solubility and poor oral bioavailability. Until there is reliable clinical evidence for its safety, efficacy and bioavailability, turmeric is not recommended for osteoarthritis.

Zingiber officinale (Ginger)

Zingiber officinale (ginger) is widely consumed as a spice in foods worldwide. It is well known as a soothing remedy for morning or motion sickness, and also for rheumatic conditions including OA (Jiménez et al., 2013). Ginger may exert anti-inflammatory actions via inhibition of COX and lipooxygenase (Kuchib et al., 1992). It has been shown in vitro to affect TNF-α and decrease synthesis of inflammatory prostaglandins in human synoviocytes (Fromolzo et al., 2004). In addition, it has been shown that ginger (and some of its active components) is effective against cytokines produced and released at sites of inflammation (Grzanna et al., 2005). Two clinical trials (sponsored by the manufacturer) have evaluated specific ginger extracts in the treatment of OA. Intake of the ginger extracts of three to six weeks duration appears to provide no relief to modest improvement in osteoarthritis pain after walking or standing (Altman and Marcussen, 2001; Bliudal et al., 2000). Ginger is safe and has been well tolerated in clinical trials; nevertheless, evidence to support its use is still rather lacking at this stage. Further evidence is required to prove its long-term safety and effectiveness.

Capsaicin

Capsaicin is an alkaloid of chilli peppers obtained from the plants of genus Capsicum, the most heavily consumed chilli throughout the world. Capsaicin and related compounds form a naturally occurring compound group called capsaicinoids, and are responsible for the characteristic pungent flavour and spiciness of chilies. Pharmacological research on capsaicin led to identification of the transient receptor potential vanilloid 1 receptor (TRPV1), which is mainly found in sensory neurons (Caterina et al., 1997). Capsaicin is a highly selective and potent agonist of TRPV1 and reduces its heat activation threshold (Korotkova et al., 2008). TRPV1 is a nonselective cation channel with high preference for Ca2+ and is mainly located in nociceptive neurons. It is activated by chemical and physical stimuli, ranging from mechanical pressure to endogenous pain inflammatory mediators such as heat, low pH, and capsaicin (O’Neill et al., 2012). Prolonged activation of TRPV1 by capsaicin is associated with pain desensitisation. Capsaicin-activated TRPV1 goes into a long refractory state, thus preventing excitatory neuron to transmit pain signals (Suzuki and Blumberg, 1999). This process known as deafferentation of nociceptive fibres has been exploited for therapeutic use of capsaicin in various painful conditions. Some studies also found an anti-inflammatory potential of capsaicin: it can inhibit paw inflammation in arthritic rats (Jee et al., 1997) and inflammation induced by ethanol at the gastric mucosa in rats (Park et al., 2000). Moreover, capsaicin was reported to inhibit NOS and COX-2 activity, as well as NF-κB pathway in macrophages independent from TRPV1 pathway (Kim et al., 2003).

Capsaicin has traditionally been used as a topical rubefacient and counterirritant to relieve pain of muscles and joints. When capsaicin is used for artistic pain it is typically used as topical preparations, in concentrations of 0.025 or 0.075%, and sold in many countries as lotions, creams and patches intended for daily skin application. Capsaicin was evaluated in a recent systematic review by the Cochrane Collaboration: topical capsaicin was reported not to be effective against osteoarthritis (Cameron and Cribb, 2013). On the contrary, one meta-analysis found enough evidence to conclude that capsaicin is effective in OA management, although there is a paucity of randomization and adequate blinding in these trials raised by the authors (de Silva et al., 2011). This is in agreement with a further meta-analysis reporting that capsaicin alleviates osteoarthritis pain (Cameron et al., 2009) and another systematic review of recent trials indicating that capsaicin is effective in reducing pain intensity in older adults with painful OA, conferring a medium sized effect (Lozett and Jones, 2014). Nonetheless, despite the promising reports above on its therapeutic use, there remains some uncertainty on whether the capsaicin effect is dose dependent, is consistent across joints, or changes over time. The current literature, at large, lacks multicenter, double blinded, randomised and vehicle-controlled studies in humans, which can ascertain the safety and efficacy of capsaicin.

LIMITATION OF THIS REVIEW

In this short review, attempts have been made to discuss some commonly used natural remedies for OA treatment. Focus of the discussion has been on the recent evidences of pharmacology, clinical efficacy and safety (whether positive or
negative) of these remedies. The aspects discussed are not exhaustive, and they only serve to give a brief overview of the pertinent literature in the field. Furthermore, this is not an all-inclusive comprehensive review of known or potential remedies. Hence the presentation is limited to those remedies where sufficient studies and/or reviews have been reported. Readers can reference some recent articles cited within the text for further information on other remedies. Lastly, scope of this review is only confined to natural remedies, both dietary supplements and herbs, and not pharmaco-therapeutic modalities currently used for OA (such as traditional Chinese medicine, manual therapy, acupuncture, and exercise programs), hence readers should refer to other relevant references for detailed review of this.

CONCLUSION

Investigations of the in vitro biological activities of glucosamine, chondroitin, S-adenosylmethionine, methylsulfonylmethane, Harpagophytum procumbens (devil’s claw), Curcuma longa (turmeric), Zingiber officinale (ginger), and capsaicin have provided some scientific support for their use in rheumatic diseases including OA. Reviews of the clinical trials on glucosamine and chondroitin provide convergent supporting evidence for safety relative to conventional drugs (such as NSAIDs), and efficacy in treating pain and inflammation in OA. However, many of these trials suffer from poor methodological quality, and further high quality clinical investigations on standardized and characterized products are necessary to provide definitive clinical evidence. Clinical trials of S-adenosylmethionine, methylsulfonylmethane, Harpagophytum procumbens (devil’s claw), Curcuma longa (turmeric), Zingiber officinale (ginger), and capsaicin are limited and offer conflicting or inconclusive results. Neither of these remedies has proven clinical usefulness due to various reasons including high cost, product quality issues, low bioavailability, and a lack of evidence on long-term safety and efficacy. Additional well-designed large trials are necessary to examine these natural remedies against standard treatments in patients with OA and to prove their clinical usefulness.

ACKNOWLEDGEMENTS

The preparation of this review is in part supported by the Monash University Seed Grant (no BCHI-SS-4-02-2010).

CONFLICT OF INTEREST

The authors have no conflicting financial interests.

REFERENCES


Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blume A, Clunbsak S. Evidence of effectiveness of herbal medicinal


Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as c-FLIP in TNF-α-stimulated HCT116 cells. NFκB and MAPKs as potential upstream targets. Int J Mol Med. 2016;37:49-57.


Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY.


Pavlovic K, Oesterov J, Olejarov M, Macek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of natural remedies for osteoarthritis


Schalée-Taraz G, Hansen C, Shabani M. Effect of a 


Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159-212.


